EGFR and non-small cell lung carcinoma: Afatinib has currently been approved for first-line treatment of metastatic NSCLC harbouring non-resistant EGFR point mutations (S768I, L861Q, or G719X), exon 19 deletions, and classical EGFR mutations [136,137].